MedTrace Logo

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

NCT04678557 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-10-18

Study results available
· View outcomes & findings →

Summary

VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.

Conditions

Interventions

COMBINATION_PRODUCT

VC-01 Combination Product

PEC-01 cells loaded into an Encaptra Drug Delivery System

Sponsors & Collaborators

  • ViaCyte

    lead INDUSTRY

Principal Investigators

  • Manasi Jaiman, MD · ViaCyte, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2021-11-12
Completion
2021-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678557 on ClinicalTrials.gov